|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al: A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pujade-Lauraine E, Ledermann JA, Selle F,
Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A,
Pignata S, et al: Olaparib tablets as maintenance therapy in
patients with platinum-sensitive, relapsed ovarian cancer and a
BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised,
placebo-controlled, phase 3 trial. Lancet Oncol. 18:1274–1284.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vegote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: The AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishi T and Forgac M: The vacuolar
(H+)-ATPases-nature's most versatile proton pumps. Nat Rev Mol Cell
Biol. 3:94–103. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Forgac M: Vacuolar ATPases: Rotary proton
pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol.
8:917–929. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marshansky V, Rubinstein JL and Grüber G:
Eukaryotic V-ATPase: Novel structural findings and functional
insights. Biochim Biophys Acta. 1837:857–879. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toyomura T, Oka T, Yamaguchi C, Wada Y and
Futai M: Three subunit a isoforms of mouse vacuolar H+-ATPase:
Preferential expression of the a3 isoform during osteoclast
differentiation. J Biol Chem. 275:8760–8765. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stransky L, Cotter K and Forgac M: The
function of V-ATPases in cancer. Physiol Rev. 96:1071–1091. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morita T, Nagaki T, Fukuda I and Okumura
K: Clastogenicity of low pH to various cultured mammalian cells.
Mutat Res. 268:297–305. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Martínez-Zaguilán R, Seftor EA, Seftor RE,
Chu YW, Gillies RJ and Hendrix MJ: Acidic pH enhances the invasive
behavior of human melanoma cells. Clin Exp Metastasis. 14:176–186.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fais S, De Milito A, You H and Qin W:
Targeting vacuolar H+-ATPases as a new strategy against cancer.
Cancer Res. 67:10627–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Holliday LS: Vacuolar H+-ATPase: An
essential multitasking enzyme in physiology and pathophysiology.
New J Sci. 2014:1–21. 2014. View Article : Google Scholar
|
|
18
|
Zhang F, Shen H, Fu Y, Yu G, Cao F, Chang
W and Xie Z: Vacuolar membrane ATPase activity 21 predicts a
favorable outcome and acts as a suppressor in colorectal cancer.
Front Oncol. 10:6058012020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishie M, Suzuki E, Hattori M, Kawaguch K,
Kataoka TR, Hirata M, Pu F, Kotake T, Tsuda M, Yamaguchi A, et al:
Downregulated ATP6V1B1 expression acidifies the intracellular
environment of cancer cells leading to resistance to
antibody-dependent cellular cytotoxicity. Cancer Immunol
Immunother. 70:817–830. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whitton B, Okamoto H, Rose-Zerilli M,
Packham G and Crabb SJ: V-ATPase Inhibition decreases mutant
androgen receptor activity in castrate-resistant prostate cancer.
Mol Cancer Ther. 20:739–748. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ibrahim SA, Kulshrestha A, Katara GK,
Riehl V, Sahoo M and Beaman KD: Cancer-associated V-ATPase induces
delayed apoptosis of protumorigenic neutrophils. Mol Oncol.
14:590–610. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Forgac M: Structure, mechanism and
regulation of the clathrin-coated vesicle and yeast vacuolar H
(+)-ATPases. J Exp Biol. 203:71–80. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Forgac M: Structure and properties of the
vacuolar (H+)-ATPases. J Biol Chem. 274:12951–1294. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bar-Peled L, Schweitzer LD, Zoncu R and
Sabatini DM: Ragulator is a GEF for the rag GTPases that signal
amino acid levels to mTORC1. Cell. 150:1196–1208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vasilyeva E, Liu Q, MacLeod KJ, Baleja JD
and Forgac M: Cysteine scanning mutagenesis of the noncatalytic
nucleotide binding site of the yeast V-ATPase. J Biol Chem.
275:255–260. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lozupone F, Borghi M, Marzoli F, Azzarito
T, Matarrese P, Iessi E, Venturi G, Meschini S, Canitano A, Bona R,
et al: TM9SF4 is a novel V-ATPase-interacting protein that
modulates tumor pH alterations associated with drug resistance and
invasiveness of colon cancer cells. Oncogene. 34:5163–5174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kalidos K, Avinash S, Prahladan A, Koshy S
and Ramachandran K: Response evaluation criteria in solid tumors
(RECIST) version 1.1 in lung cancer: comparison with RECIST version
1.0-a retrospective study 2016: European Society of Radiology
(ECR). 2016.PubMed/NCBI
|
|
28
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hendrix ND, Wu R, Kuick R, Schwartz DR,
Fearon ER and Cho KR: Fibroblast growth factor 9 has oncogenic
activity and is a downstream target of Wnt signaling in ovarian
endometrioid adenocarcinomas. Cancer Res. 66:1354–1362. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bowen NJ, Walker LD, Matyunina LV, Logani
S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling
supports the hypothesis that human ovarian surface epithelia are
multipotent and capable of serving as ovarian cancer initiating
cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elgaaen BV, Olstad OK, Sandvik L, Odegaard
E, Sauer T, Staff AC and Gautvik KM: ZNF385B and VEGFA are strongly
differentially expressed in serous ovarian carcinomas and correlate
with survival. PLoS One. 7:e463172012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ahmed AA, Mills AD, Ibrahim AE, Temple J,
Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, et
al: The extracellular matrix protein TGFBI induces microtubule
stabilization and sensitizes ovarian cancers to paclitaxel. Cancer
Cell. 12:514–527. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bushnell B: BBMap. https://sourceforge.net/projects/bbmap/July
17–2022
|
|
34
|
Andrews S: FastQC: A quality control tool
for high throughput sequence data. Available online. Retrieved May.
17:20182010.
|
|
35
|
Dobin A, Davis CA, Schlesinger F, Drenkow
J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR:
Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Anders S, Pyl PT and Huber W: HTSeq-a
Python framework to work with high-throughput sequencing data.
Bioinformatics. 31:166–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bast RC Jr, Feeney M, Lazarus H, Nadler
LM, Colvin RB and Knapp RC: Reactivity of a monoclonal antibody
with human ovarian carcinoma. J Clin Invest. 68:1331–1337. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu-Rice Y, Edassery SL, Urban N, Hellstrom
I, Hellstrom KE, Deng Y, Li Y and Luborsky JL: Selenium-Binding
Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian
cancer. Reproduction. 153:277–284. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shin HY, Yang W, Lee EJ, Han GH, Cho H,
Chay DB and Kim JH: Establishment of five immortalized human
ovarian surface epithelial cell lines via SV40 T antigen or HPV
E6/E7 expression. PLoS One. 13:e02052972018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hothorn T and Lausen B: Maximally selected
rank statistics in R. R News. 2:3–5. 2002.
|
|
42
|
Li X, Li H, Yang C, Liu L, Deng S and Li
M: Comprehensive analysis of ATP6V1s family members in renal clear
cell carcinoma with prognostic values. Front Oncol. 10:5679702020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Counis MF and Torriglia A: Acid DNases and
their interest among apoptotic endonucleases. Biochimie.
88:1851–1858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Martinez-Zaguilan R, Lynch RM, Martinez GM
and Gillies RJ: Vacuolar-type H (+)-ATPases are functionally
expressed in plasma membranes of human tumor cells. Am J Physiol.
265:C1015–C1029. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Barar J and Omidi Y: Dysregulated pH in
tumor microenvironment checkmates cancer therapy. Bioimpacts.
3:149–162. 2013.PubMed/NCBI
|
|
46
|
Hong J, Yokomakura A, Nakano Y, Ishihara
K, Kaneda M, Onodera M, Nakahama K, Morita I, Niikura K, Ahn JW, et
al: Inhibition of vacuolar-type (H+)-ATPase by the cytostatic
macrolide apicularen A and its role in apicularen A-induced
apoptosis in RAW 264.7 cells. FEBS Lett. 580:2723–2730. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wojtkowiak JW, Rothberg JM, Kumar V,
Schramm KJ, Haller E, Proemsey JB, Lloyd MC, Sloane BF and Gillied
RJ: Chronic autophagy is a cellular adaptation to tumor acidic pH
microenvironments. Cancer Res. 72:3938–3947. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
McConnell M, Feng S, Chen W, Zhu G, Shen
D, Ponnazhagan S, Deng L and Li YP: Osteoclast proton pump
regulator Atp6v1c1 enhances breast cancer growth by activating the
mTORC1 pathway and bone metastasis by increasing V-ATPase activity.
Oncotarget. 8:47675–47690. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chueca E, Apostolova N, Esplugues JV,
García-González MA, Lanas Á and Piazuelo E: Proton pump inhibitors
display antitumor effects in Barrett's adenocarcinoma cells. Front
Pharmacol. 7:4522016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hinton A, Bond S and Forgac M: V-ATPase
functions in normal and disease processes. Pflugers Arch.
457:589–598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ohta T, Numata M, Yagishita H, Futagami F,
Tsukioka Y, Kitagawa H, Kayahara M, Nagakawa T, Miyazaki I,
Yamamoto M, et al: Expression of 16 kDa proteolipid of
vacuolar-type H(+)-ATPase in human pancreatic cancer. Br J Cancer.
73:1511–1517. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chung C, Mader CC, Schmitz JC, Atladottir
J, Fitchev P, Cornwell ML, Koleske AJ, Crawford SE and Gorelick F:
The vacuolar-ATPase modulates matrix metalloproteinase isoforms in
human pancreatic cancer. Lab Invest. 91:732–743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lu Q, Lu S, Huang L, Wang T, Wan Y, Zhou
CX, Zhang C, Zhang Z and Li X: The expression of V-ATPase is
associated with drug resistance and pathology of non-small-cell
lung cancer. Diagn Pathol. 8:1452013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
García-García A, Pérez-Sayáns M, Rodríguez
MJ, Antúnez-López J, Barros-Angueira F, Somoza-Martín M,
Gándara-Rey JM and Aguirre-Urízar JM: Immunohistochemical
localization of C1 subunit of V-ATPase (ATPase C1) in oral squamous
cell cancer and normal oral mucosa. Biotech Histochem. 87:133–139.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pérez-Sayáns M, Reboiras-López MD,
Somoza-Martín JM, Barros-Angueira F, Diz PG, Rey JM and
García-García A: Measurement of ATP6V1C1 expression in brush
cytology samples as a diagnostic and prognostic marker in oral
squamous cell carcinoma. Cancer Biol Ther. 9:1057–1064. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kulshrestha A, Katara GK, Ibrahim S,
Pamarthy S, Jaiswal MK, Sachs AG and Beaman KD: Vacuolar ATPase
‘a2’ isoform exhibits distinct cell surface accumulation and
modulates matrix metalloproteinase activity in ovarian cancer.
Oncotarget. 6:3797–3810. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Song T, Jeon HK, Hong JE, Choi JJ, Kim TJ,
Choi CH, Bae DS, Kim BG and Lee JW: Proton pump inhibition enhances
the cytotoxicity of paclitaxel in cervical cancer. Cancer Res
Treat. 49:595–606. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lim JH, Park JW, Kim MS, Park SK, Johnson
RS and Chun YS: Bafilomycin induces the p21-mediated growth
inhibition of cancer cells under hypoxic conditions by expressing
hypoxia-inducible factor-1alpha. Mol Pharmacol. 70:1856–1865. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Webb BA, Chimenti M, Jacobson MP and
Barber DL: Dysregulated pH: A perfect storm for cancer progression.
Nat Rev Cancer. 11:671–677. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rishi G, Huang G and Subramaniam VN:
Cancer: The role of iron and ferroptosis. Int J Biochem Cell Biol.
141:1060942021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Torti SV and Torti FM: Iron and cancer:
More ore to be mined. Nat Rev Cancer. 13:342–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji
RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, et al:
Addressing safety liabilities of TfR bispecific antibodies that
cross the blood-brain barrier. Sci Transl Med. 5:183ra572013.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Deng Z, Manz DH, Torti SV and Torti FM:
Iron-responsive element-binding protein 2 plays an essential role
in regulating prostate cancer cell growth. Oncotarget.
8:82231–82243. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shen J, Sheng X, Chang Z, Wu Q, Wang S,
Xuan Z, Li D, Wu Y, Shang Y, Kong X, et al: Iron metabolism
regulates p53 signaling through direct heme-p53 interaction and
modulation of p53 localization, stability, and function. Cell Rep.
7:180–193. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Falzone L, Scandurra G, Lombardo V,
Gattuso G, Lavoro A, Distefano AB, Scibilia G and Scollo P: A
multidisciplinary approach remains the best strategy to improve and
strengthen the management of ovarian cancer (Review). Int J Oncol.
59:532021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Rojas V, Hirshfield KM, Ganesan S and
Rodriguez-Rodriguez L: Molecular characterization of epithelial
ovarian cancer: Implications for diagnosis and treatment. Int J Mol
Sci. 17:21132016. View Article : Google Scholar : PubMed/NCBI
|
